Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Molecular Profiling Protocol (SCRI-CA-001)
NCT00530192 · View on ClinicalTrials.gov ↗
Study Summary
This is an open-label, multicenter pilot study in patients with advanced solid tumors. The primary objective of this study is to compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has progressed on. To be eligible, patients must have received at least two lines of prior chemotherapeutic, hormonal or biological regimens for advanced disease, have measurable or evaluable, refractory disease and have clear documentation of the time between treatment start and documented progression on the last treatment prior to study entry. Eligible patients must undergo or have available a tumor biopsy for molecular profiling within 2 months of IHC/FISH and/or DNA microarray analysis.
Conditions Studied
Interventions
- OTHER Treatment based on Molecular Profiling
Study Locations (9)
Arizona
- TGen Clinical Research Services — Scottsdale
- Mayo Clinic — Scottsdale
California
- Tower Oncology — Beverly Hills
- Louis Warschaw Prostate Cancer Center at Cedars Sinai Medical Center — Los Angeles
Texas
- South Texas Oncology Hematology — San Antonio
- Tyler Cancer Center — Tyler
Alabama
- Oncology Specialties — Huntsville
Indiana
- Central Indiana Cancer Center — Indianapolis
South Carolina
- Cancer Center of the Carolinas — Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00530192
The ClinicalTrials.gov registry entry for NCT00530192 describes a study currently listed as completed. It is categorized as Early Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scottsdale Healthcare, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Refractory Cancer appearing as the primary indexed condition, and to 1 intervention — of which Treatment based on Molecular Profiling is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00530192 reports 9 study locations spanning 6 distinct geographic areas — top geographies include Arizona, California, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00530192 about?
NCT00530192 is a clinical study titled "Molecular Profiling Protocol (SCRI-CA-001)". This is an open-label, multicenter pilot study in patients with advanced solid tumors. The primary objective of this study is to compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has pro...
What is the current status of trial NCT00530192?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 86 participants. The study started on 2006-09. Estimated completion is 2009-03.
What conditions does trial NCT00530192 study?
This clinical trial studies the following conditions: Refractory Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00530192?
The interventions under investigation include: Treatment based on Molecular Profiling (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00530192?
This trial is sponsored by Scottsdale Healthcare, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00530192 being conducted?
This trial has 9 study locations across Alabama, Arizona, California, Indiana, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.